Press Contact

If you would like to find out more about Abiomed® and the Impella® heart pumps, or if you have any questions, please do not hesitate to contact us.

Contact

Dr. Sebastian Heindrichs

Associate Director European Communications
ABIOMED Europe GmbH
Neuenhofer Weg 3 | 52074 Aachen,  Germany
E-Mail: sheindrichs(at)abiomed.com
Phone: +49 (0)151 7447 2278

Press Releases

November 5, 2020

First 1,000 Patients Treated with Impella 5.5 with SmartAssist, a Heart Pump Designed for Surgeons

https://www.businesswire.com/news/home/20201105005280/en/First-1000-Patients-Treated-with-Impella-5.5-with-SmartAssist-a-Heart-Pump-Designed-for-Surgeons


October 28, 2020

First Patients Treated with the World’s Smallest Heart Pump, the 9Fr Impella ECP

https://www.businesswire.com/news/home/20201028005398/en/First-Patients-Treated-with-the-World%E2%80%99s-Smallest-Heart-Pump-the-9Fr-Impella-ECP


October 26, 2020

FDA Grants 510(k) Clearance for Abiomed’s Innovative Cardiopulmonary Support Technology

https://www.businesswire.com/news/home/20201026005299/en/FDA-Grants-510-Clearance-Abiomed%E2%80%99s-Innovative-Cardiopulmonary


October 16, 2020

Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women

https://www.businesswire.com/news/home/20201016005118/en/Data-Presented-at-TCT-Connect-Finds-Pre-PCI-Use-of-Impella-for-AMI-Cardiogenic-Shock-is-Associated-with-Higher-Survival-Particularly-in-Women


October 16, 2020

Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP

https://www.businesswire.com/news/home/20201016005123/en/Studies-Presented-at-TCT-Connect-Associate-Higher-Survival-With-Early-Identification-of-Right-Heart-Failure-and-Early-Use-of-Impella-RP


October 15, 2020

Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization with Impella Leads to Improved Outcomes

https://www.businesswire.com/news/home/20201015005176/en/Largest-Study-of-Hemodynamically-Supported-High-Risk-PCI-Patients-Finds-More-Complete-Revascularization-with-Impella-Leads-to-Improved-Outcomes


October 14, 2020

Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves Left Ventricular Ejection Fraction

https://www.businesswire.com/news/home/20201014005286/en/Restore-EF-Study-Demonstrates-Impella-Supported-High-Risk-PCI-Improves-Left-Ventricular-Ejection-Fraction


October 8, 2020

TCT Connect to Highlight How Impella Enables Improved Outcomes for High-Risk PCI, Cardiogenic Shock and Right Heart Failure Patients

https://www.businesswire.com/news/home/20201008005283/en/TCT-Connect-Highlight-Impella-Enables-Improved-Outcomes


July 30, 2020

Large Multi-Center Study in Japan Finds High Survival Rates with Use of Impella Heart Pump

https://www.businesswire.com/news/home/20200730005307/en/Large-Multi-Center-Study-Japan-Finds-High-Survival
PDF Download


July 1, 2020

Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssist

https://www.businesswire.com/news/home/20200701005293/en/Study-Finds-84-Survival-Rate-Patients-Cardiogenic
PDF Download


June 16, 2020

Abiomed Launches Virtual Physician Education Program, CAMP PCI, to Improve High-Risk PCI Patient Outcomes

https://www.businesswire.com/news/home/20200616005314/en/Abiomed-Launches-Virtual-Physician-Education-Program-CAMP
PDF Download


June 5, 2020

FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump

https://www.businesswire.com/news/home/20200605005049/en/FDA-Approves-Abiomed%E2%80%99s-First-in-Human-Trial-Impella-ECP
PDF Download


May 19, 2020

PROTECT III Study Shows Placing Impella Prior to High-Risk PCI is Associated with Lower Mortality Compared to Bailout PCI

https://www.businesswire.com/news/home/20200519005627/en/PROTECT-III-Study-Shows-Placing-Impella-Prior
PDF Download


April 29, 2020

Abiomed Expands Product Portfolio with Acquisition of Cardiopulmonary Support Technology (ECMO) to Improve Outcomes for Patients

https://www.businesswire.com/news/home/20200429005975/en/Abiomed-Expands-Product-Portfolio-Acquisition-Cardiopulmonary-Support
PDF Download


May 21, 2019

National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery

PDF Download


April 4, 2019

Cardiogenic Shock Survival Rates Improve Significantly in Three Years Since Impella FDA PMA Approval

PDF Download


DE / EN